Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?

Archives of Medical Science

Volumn 8, Issue 3, 2012, Pages 528-532

  Zaborowska, Magdalena ^a   Szmit, Sebastian ^a,b   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiogenesis inhibitor; Castrate resistant prostate cancer; Sorafenib

Indexed keywords

MORPHINE; NARCOTIC ANALGESIC AGENT; PROSTATE SPECIFIC ANTIGEN; SORAFENIB;

ALOPECIA; BONE METASTASIS; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; NAUSEA; NOTE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84863909624     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.29408     Document Type: Note

References (20)

1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-2.
2. Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12. (Pubitemid 39315317)
3. Safarinejad MR. Combination chemotherapy with docetaxel, estramustine, and suramin for hormone refractory prostate cancer. Urol Oncol 2005; 23: 93-101. (Pubitemid 40616299)
4. Raghavan D, Brandes LJ, Klapp K, et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol 2005; 174: 1808-3.
5. Kozłowska E, Szewczyk MT, Banaszkiewicz Z, Jawień A, Cierzniakowska K, Jarmocik P. Knowledge of symptoms and diagnostic possibilities of cancer diseases. Arch Med Sci 2011; 7: 304-9.
6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer v1.2011, www.nccn.org.
7. Erlich S, Tal-Or P, Liebling R, et al. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 72: 427-36. (Pubitemid 44061749)
8. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84. (Pubitemid 29048852)
9. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci Lond 2005; 108: 293-308. (Pubitemid 40516993)
10. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73: 678-87. (Pubitemid 24046612)
11. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160: 459-65. (Pubitemid 29476698)
12. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 2070-6.
13. Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormonerefractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 1480-5. (Pubitemid 350175850)
14. Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 746-51. (Pubitemid 351461047)
15. Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-14. (Pubitemid 351377997)
16. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-40.
17. Safarinejad MR. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a phase II study. Urol Oncol 2010; 28: 21-7.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
19. Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1 (2 Suppl): S41-54.
20. Maitland ML, Bakris GL, Black HR, et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.